Compare Eli Lilly And Co (LLY) vs Shell PLC (SHEL) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

Shell (SHEL) trades at $86.20, down 1.28% on the day, with strong technical momentum as moving averages signal bullish sentiment. The company maintains solid fundamentals with a P/E of 13.6 and net income margin of 7.01%, though revenue has declined from $381.3B in 2022 to $266.9B in 2025. Recent developments include expansion in Caribbean LNG infrastructure and the pending $16.4B acquisition of ARC Resources, positioning for strategic growth despite Middle East production disruptions.

Outlook remains positive with analyst consensus at Buy (69%) and $114.13 price target, representing 32% upside. Key risks include geopolitical volatility affecting oil prices and ongoing production challenges. The stock offers value through discounted valuation metrics and dividend yield, though investors should monitor execution on growth initiatives and energy market stability.